At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed hepatocellular carcinoma not amenable to curative resection
- ✓Measurable disease per RECIST criteria
- ✓Up to one prior systemic therapy allowed, with any prior therapy completed ≥30 days prior to study entry
- ✓ECOG performance status ≤2
- ✕Prior VEGF- or EGFR-targeted therapy
- ✕Prior malignancy other than non-melanoma skin cancer or cervical dysplasia within 5 years
- ✕History of ruptured HCC or HCC with large necrotic areas
- ✕Corneal abnormalities (dry eye syndrome, Sjögren's syndrome, Fuchs' dystrophy)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of the Combination of Bevacizumab and Erlotinib in Patients With Unresectable Hepatocellular Carcinoma
In Brief
A Phase 2 clinical trial evaluating Bevacizumab (Avastin) and Erlotinib for Hepatocellular Carcinoma and Liver Cancer. Completed, enrolled 62 participants across 1 site.
Detailed Summary
The primary objective will be to assess progression-free survival (PFS) measured at 16 weeks following initiation of therapy with the combination of Avastin and erlotinib in patients with unresectable hepatocellular carcinoma (HCC). Progression-free survival is defined as the time from initiation of therapy until documented disease progression or death. Secondary objectives include: response rate, median and overall survival, toxicity and tolerability, and to ascertain whether there is any correlation of response with prior treatment status and underlying HCC risk factor(s).
Study Details
Timeline
Interventions
10 mg/kg IV every 14 days, repeat cycle every 28 days
150 mg orally every day continuous dosing, repeat cycle every 28 days